Article Details
Retrieved on: 2024-07-26 12:33:09
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Sugemalimab becomes the world's first anti-PD-L1 monoclonal antibody (mAb) approved in Europe for first-line treatment of both squamous and non- ...
Article found on: www.morningstar.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here